Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3357548 | 0.93 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL30982820 | 0.85 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL30982659 | 0.85 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL30982466 | 0.85 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3355462 | 0.84 | HTT (0.53) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3355255 | 0.84 | HTT (0.55) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL2270758 | 0.83 | HTT (0.68) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL2279184 | 0.81 | SMN1; SMN2 (0.49) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3361358 | 0.77 | HTT (0.46) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL10402472 | 0.76 | MEN1 (0.65) | HTTSMN1; SMN2MEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110200536-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | GE HEALTHCARE AS (NO) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200536-A1 | CHELATORS, PARAMAGNETIC CHELATES THEREOF AND THEIR USE AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING (MRI) | TSPO, PML, AIP | HTT 410/4885SMN1; SMN2 2492/4885MEN1 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.